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The early detection and eradication of circulating tumor cells (CTCs) play an important role in cancer
metastasis management. This paper describes a new nanoparticle-enabled technique for integrated
enrichment, detection and killing of CTCs by using magnetic nanoparticles and bismuth nanoparticles,
X-ray fluorescence spectrometry, and X-ray radiation. The nanoparticles are modified with tumor
targeting agents and conjugated with tumor cells through folate receptors over-expressed on cancer
cells. A permanent micro-magnet is used to collect CTCs suspended inside a flowing medium that
contains phosphate buffered saline (PBS) or whole blood. The characteristic X-ray emissions from
collected bismuth nanoparticles, upon excitation with collimated X-rays, are used to detect CTCs.
Results show that the method is capable of selectively detecting CTCs at concentrations ranging from
100–100,000 cells/mL in the buffer solution, with a detection limit of 100 CTCs/mL. Moreover, the
dose of primary X-rays can be enhanced to kill the localized CTCs by radiation induced DNA damage,
with minimal invasiveness, thus making in vivo personalized CTC management possible.
& 2012 Elsevier B.V. All rights reserved.1. Introduction
Early diagnosis and treatment of cancer are highly important
for reducing mortality and recurrence probability (Wulfkuhle
et al., 2003). The five year survival rate of patients with localized
breast cancers is 95%, while that of patients with metastatic
cancer reduces to 30%, which highlights the importance of early
detection in cancer management (Heimann and Hellman, 2000).
Detecting circulating tumor cells (CTCs) released inside blood
stream of patients during cancer development could provide a
sensitive and minimally invasive way to monitor cancer progressll rights reserved.
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logy Center, University of
his work.(Kaiser, 2010; Liu et al., 2009; Nezos et al., 2011; Sun et al., 2011).
But, it is challenging to detect CTCs in blood, because CTCs in early
stage cancer patients are extremely rare (1 CTC in 7.5 mL of blood
or 1 CTC against 103–107 nucleated cells in blood) (Yu et al.,
2011). An enrichment step is required prior to CTC detection
(Pantel et al., 2008; Zemp, 2009). Many techniques have been
used for CTC enrichment such as microfluidic CTC chips
(Dharmasiri et al., 2011; He et al., 2007; Nagrath et al., 2007;
Wang et al., 2011a), magnetic particles (Benez et al., 1999;
Bilkenroth et al., 2001; Zborowski and Chalmers, 2011), micro-
filtration (Lin et al., 2010; Zheng et al., 2007; Zheng et al., 2011),
dielectric separation (Gascoyne et al., 2009), and flow cytometry
(Georgakoudi et al., 2004; Hu et al., 2010; Zharov et al., 2006).
These methods are dependent on physical properties of tumor
cells (size, mechanical stiffness, or dielectric property), or surface
receptors over-expressed on tumor surfaces. Once collected, CTCs
can be detected with fluorescence method (Hsieh et al., 2006;
Kojima et al., 2009), photoacoustic method (Galanzha et al., 2009;
Gutierrez-Juarez et al., 2010; Nedosekin et al., 2010; Weight et al.,
2006), electrical method (Chung et al., 2011), flow cytometry, cell
counting, and Raman spectroscopy (Neugebauer et al., 2010; Sha
et al., 2008; Wang et al., 2011b). Though these methods have
shown the prospects of CTCs in cancer management, existing CTC















Fig. 1. Nanoparticle enabled integrated enrichment, detection and killing
of circulating tumor cells.
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hundred, which can be partly due to tumor heterogeneity in
patient and complex nature of blood, but is more likely due to
variation in collection or detection efficiency of different meth-
ods; (2) CTC detection has not been seamlessly integrated with
treatment, thus patients will have to wait for certain time before
treatment starts, which can lead to tumor metastasis to distant
organ; (3) chemotherapy is often used for CTC treatments, but
drugs used in chemotherapy are toxic to normal cells, and there is
no localized treatment option available for CTCs. If CTCs could be
killed locally and non-invasively, damage to normal cells will be
minimized, and there is no need to use invasive treatments such
as surgery. Nanostructured materials (i.e., golden carbon nano-
tubes and magnetic nanoparticles) have been used in combina-
tion to capture and detect CTCs, but the method needs
complicated photoacoustic devices for CTC detection, and tumor
killing is not integrated (Galanzha et al., 2009). CTC detections
have also been achieved in vivo using flow cytometry after
labeling CTCs with fluorescent probes that target surface recep-
tors of CTCs (He et al., 2007), but the method does not take CTC
removal or elimination into consideration.
X-ray fluorescence (XRF) has been used to detect multiple DNA
and protein biomarkers by using metallic nanoparticles as probes
(Hossain et al., 2010). XRF spectrometry is a widely used analy-
tical method for detecting trace elements in various samples due
to its high sensitivity, specificity and simplicity (Hatzistavros
et al. (2007); Mann et al., 2000). The characteristic X-ray emis-
sions from elements, present in the X-ray irradiated samples, are
detected using an X-ray spectrometer. The amount of each
element present in the sample can be quantified based on the
intensity of according XRF peak. Bismuth nanoparticles are
promising candidates for biomarker detection, cancer imaging
and therapy due to bismuth’s large atomic number (83) and
relatively low toxicity (Rabin et al., 2006). Meanwhile, super-
paramagnetic iron oxide nanoparticles are well known for their
enrichment capability and biocompatibility and have been widely
applied in detection of rare analytes (Bhattacharya et al., 2011).
This paper describes an integrated method that can be used for
in vivo CTC management by combining magnetic nanoparticle
based capture, XRF based detection and X-ray radiation killing of
CTCs. The feasibility of this integrated approach has been con-
firmed in this proof-of-concept in vitro experiment: superpara-
magnetic iron oxide nanoparticles and X-ray absorbing bismuth
nanoparticles are modified by folic acid (FA) ligands that bind to
folate receptors (FR) over-expressed on tumor cell surfaces; after
adding both nanoparticles in cell suspension, nanoparticles can
bind on surfaces of tumor cells; a micro-magnet allows localiza-
tion of CTCs in a small area (preferentially underneath the skin in
case of in vivo detection); an incoming X-ray beam excites the
characteristic X-rays of bismuth nanoparticles, signaling the
presence of CTCs; subsequently, X-ray intensity can be increased
to damage DNA of CTCs and kill CTCs locally (Fig. 1).2. Materials and methods
2.1. Materials
HeLa (CLL-2) and MG-63 (CRL-1427) cell lines are obtained from
American Type Culture Collection (ATCC, Manassas, VA). 3(4,5-
dimethylthiazol)-2-diphenyltertrazolium bromide (MTT) kit for
mammalian cells is supplied by Invitrogen (Carlsbad, CA). Single
donor human whole blood containing anticoagulant of ethylenedia-
minetetraacetic acid (EDTA) is obtained from Innovative Research
(Novi, MI). FA is obtained from VWR (West Chester, PA). Hydrated
bismuth nitrate (Bi(NO3)3 5H2O), sodium borohydride (NaBH4),RPMI 1640 culture media, penicillin, streptomycin, fetal bovine
serum (FBS), and Dulbecco’s phosphate-buffered saline (D-PBS)
are from Sigma-Aldrich (St. Louis, MO). Ultrapure water
(18.2 MO cm1) from Nanopure System (Barnstead, Kirkland,
WA) is used throughout. All the other chemicals are obtained
from VWR (West Chester, PA) and used as received.
2.2. Nanoparticle synthesis
Iron oxide nanoparticles are synthesized as follows: 1 mmol of
Fe(acac)3 and 4 mmol of 1,2-dodecanediol are dissolved into a
mixture of 10 mL of benzyl ether, 3 mL of oleic acid and 1 mL of
oleylamine. The mixture is then dehydrated at 110 1C under argon
flow for 1 h, and heated up to 200 1C for 30 min, and at 290 1C for
2.5 h. After cooling to room temperature, 30 mL of anhydrous
ethanol is added in the mixture to separate nanoparticles. The
nanoparticles collected by centrifugation (7000 rpm, 10 min) are
washed with ethanol and dispersed in hexane. After precipitated
with acetone, the nanoparticles are dispersed in 1 mol/L ammonia
in isopropanol, sonicated for 30 min, centrifuged, and washed
with acetone, toluene and ethanol to remove oleic acid and
oleylamine.
Bismuth nanoparticles are made as follows: 0.1 mmol of Bi
(NO3)3 and 0.5 mmol of poly (vinylpyrroldone) (PVP) are dis-
solved in 10 mL of N,N-dimethylformamide (DMF). The mixture is
degassed with argon for 15 min under stirring. 0.3 mL of 1 mol/L
NaBH4 in water is mixed with 10 mL of DMF and added in the
mixture of Bi(NO3)3 and PVP under vigorous stirring and argon
flow for 5 min. The nanoparticles are precipitated by adding
acetone, followed by centrifugation, washing with acetone and
drying in vacuum. A JEOL 1011 transmission electron microscope
(TEM) operated at 100 kV is used to derive the size and shape of
the synthesized nanoparticles.
2.3. Conjugation of nanoparticles with folic acid
The conjugation of FA with iron oxide nanoparticles and
bismuth nanoparticles is carried out as follows (Zhang et al.,
2002): both nanoparticles are washed twice in ethanol, centri-
fuged, dried at 110 1C for 1 h, and vacuum-dried overnight to
remove adsorbed water. 15 mg of dried nanoparticles are dis-
persed in 3 mmol/L (3-aminopropyl)-triethoxysilane (APTES) in
M. Hossain et al. / Biosensors and Bioelectronics 38 (2012) 348–3543505 mL toluene. The mixture is sonicated and incubated at 60 1C for
4 h. The suspension is centrifuged, and the precipitates are
sonicated in toluene for 10 min, and washed with toluene and
ethanol. The precipitates are then added to the mixture of 1 mL of
10 mmol/L FA solution in 500 mL of dimethylsulfoxide (DMSO),
1.5 mL of 15 mmol/L N-hydroxysuccinimide (NHS), and 1.5 mL
of 75 mmol/L 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide
(EDC) solution in water, using triethylamine as a catalyst. After
adjusting pH to 9 and incubation at 37 1C for 4 h, the suspension
is centrifuged, and precipitate is washed with deionized water
and vacuum-dried overnight. FA-modified nanoparticles are
redispersed in phosphate buffered saline (PBS) to 1 mg/mL, and
stored in refrigerator. The hydrodynamic diameter of FA conju-
gated nanoparticles in PBS is measured by dynamic light scatter-
ing (DLS) with PD2000 DLS detector. The covalent bonding of FA
with the nanoparticles is confirmed using Fourier transform
infrared spectroscopy (FTIR).
2.4. Cell culture and nanoparticles treatment
Human adenocarcinoma HeLa cells and human osteosarcoma
MG-63 cells are cultured in 75 cm2 flasks that contain 15 mL
RPMI-1640 medium supplemented with 10% FBS and 5% penicil-
lin at 37 1C with 5% CO2. When cells become 80% confluence, an
equimolar mixture of 100 mg/mL of FA-conjugated iron oxide
nanoparticles in PBS (1013 particles/mL) and 100 mg/mL of FA
conjugated bismuth nanoparticles in PBS (1011 particles/ml) is
added to the petri dish containing the cultured cells (1105).
After incubating for 24 h (37 1C and 5% CO2), the cells are rinsed
five times in PBS to remove any unbound or non-specifically
bound nanoparticles. The cells are then detached from flasks by
incubating with trypsin-EDTA solution at 37 1C for 5 min, fol-
lowed by centrifugation at 1000 rpm for 8 min, before being
redispersed in PBS and introduced into an in vitro circulating
system designed to mimic human blood flow.
2.5. Setup for CTC capture, detection and killing
A Mini-X portable X-ray tube (Amptek, Bedford, MA) with a
silver anode operating at 30 kV and 15 mA is used to produce
primary X-rays. The tube is fitted with a series of brass and
tungsten collimators to reduce outgoing beam size from 2 mm to
400 mm in diameter. An X-ray spectrometer (Amptek X-123) with
Si-PIN photodiode is used to analyze XRF emissions in the
transmission mode. The X-ray spectrometer contains a solid-state
detector, a digital pulse processor and a multichannel analyzer,
which are interfaced with a computer for data acquisition and
analysis. A 25 mm thick silver filter and a 250 mm thick aluminum
filter are used in combination to reduce background and improve
signal-to-noise ratio (SNR) in low energy region (0–15 keV) of the
XRF spectrum. A neodymium–iron–boron micro-magnet obtained
from BJA Magnetics (Leominster, MA) with diameter of 300 mm,
length of 2.5 mm and field strength of 0.5 mT is attached onto one
side of a polyethylene tube of 1 mm inner diameter. The distance
between X-ray source and the tube, and that between the tube
and detector are 2 and 1 cm, respectively. HeLa cells (1105)
containing FA conjugated bismuth nanoparticles and iron oxide
nanoparticles at a concentration of 100 mg/mL are dispersed in
1 mL of PBS. The cell-nanoparticle conjugates are pumped
through the tube with a micro-syringe pump (Fisher Scientific,
NJ) at a pulsatile flow rate of 0.1 cm/s (close to that in human
body), and are captured by the micro-magnet on the internal wall
of tube just underneath the X-ray source. The captured CTCs are
exposed to X-rays for 10 min. The XRF peaks from bismuth
nanoparticles at 10.86 and 13.02 keV are used to determine
the presence of CTCs. The XRF emissions from iron oxidenanoparticles are not used for CTC detection, because the magnet
attached to the side of the tube also gives off characteristic iron
peaks in the XRF spectrum. To kill captured HeLa cells through
radiation induced DNA damage, the X-ray dose is increased by
increasing the exposure time to 60 min and the tube voltage to
40 kV.
To evaluate the performance of our method in detecting CTCs
in whole blood, the flowing PBS is replaced with human blood
spiked with HeLa or MG-63 cells at a concentration of 104 cells/
mL. The cultured cells have been incubated for 24 h with FA
conjugated bismuth nanoparticles and iron oxide nanoparticles at
a concentration of 100 mg/mL followed by PBS wash for five times
before adding to the whole blood. The spiked blood samples are
diluted (10 ) with PBS to ensure a steady flow inside the tube by
preventing any agglomeration or coagulation. The captured cells
are exposed to X-rays for 10 min at 30 kV and 15 mA and XRF
counts for the bismuth peak at 10.86 keV are recorded. To serve as
control, a background spectrum is also collected using diluted
blood samples.
2.6. Comet assay
In order to test DNA damage, X-ray irradiated HeLa cells in
1 mL of 1X PBS are added into 2% low melting point agarose at a
1:1 volume ratio at 37 1C. 300 mL of the cell-agarose suspension is
dropped onto each of three 43 cm2 GelBond slides and allowed
to settle at 37 1C for 10 min. The agarose is solidified by placing
GelBond slides at 4 1C for 10 min. The irradiated cells are lysed by
immersing slides in lysis buffer (10 mmol/L Tris–HCl, 100 mmol/L
Na2EDTA, 2.5 mol/L NaCl, 1% Triton X-100) at pH 10 and 4 1C for
1 h. The slides are placed in an electrophoresis chamber filled
with alkaline buffer (0.3 mol/L NaOH and 1 mmol/L Na2EDTA) for
40 min. The electrophoresis is carried out for 30 min by applying
an 18V dc voltage across the chamber at 1 V/cm and 300 mA.
Short strands of damaged DNA diffuse out of cells and migrate
towards the anode. The slides are neutralized twice for 10 min in
fresh buffer (0.4 mol/L Tris–HCl at pH 7.5) and stained with
5 mg/mL of ethidium bromide (EB) aqueous solution for 30 min.
The EB-labeled cells on GelBond slides are observed with epi-
fluorescence microscope (Olympus BX51M) at magnification 10
and images are recorded using a computer. Images of over 100
randomly selected non-overlapping cells are analyzed for each
sample using CometScore software (TriTek Corp., Sumerduck, VA).
2.7. MTT assay
X-ray irradiated HeLa cells are transferred into the microwells
of a 96-well sterile microplate (BD Falcon) containing 100 mL of
media. After incubation for 24 h, the medium in each well is
removed and replaced with 100 mL of fresh culture medium.
10 mL of the 12 mmol/L MTT stock solution is added in each well
and a negative control (100 mL of medium without nanoparticles).
After incubation at 37 1C for 4 h, 100 mL of sodium dodecyl
sulfate–hydrochloric acid solution is added and mixed thoroughly
using pipette. After incubating at 37 1C inside a humidified
chamber for 6 h, each sample is mixed with pipette and optical
absorbance at 570 nm is recorded.
2.8. Statistical analysis
Seven independent experiments (n¼7) have been carried out for
each data set and the results are expressed as mean7standard error
of the mean (SEM). Statistical analyses were performed using SPSS
16.0 (SPSS Inc., Chicago, Illinois). One-way ANOVA and LSD tests
were applied to compare the results from samples treated by
different methods. po0.05 was considered statistically significant.
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3.1. Characterization of nanoparticles
Fig. 2A and B are the transmission electron microscope (TEM)
images of nanoparticles made using colloidal methods, where the
average diameters of bismuth nanoparticles (Fig. 2A) and iron
oxide nanoparticles (Fig. 2B) are 30 and 10 nm, respectively.
Fig. 2C shows DLS measurements from FA conjugated iron oxide
nanoparticles in PBS with a size range of 10–45 nm and a mean
diameter of 30 nm. Fig. 2C inset shows FA conjugated bismuth
nanoparticles in PBS with a size range of 70–95 nm and a mean
diameter of 80 nm. These results demonstrate that nanoparticles
form small agglomerates, which are uniformly distributed in PBS.
The FTIR spectrum in Fig. 2D for FA conjugated bismuth nano-
particles shows the presence of C–N peak (1000–1250 cm1) and
NH2 scissoring peaks (1550–1650 cm
1), indicating successful
conjugation of FA with bismuth nanoparticles. The conjugation
of FA with iron oxide nanoparticles has also been confirmed (data
not shown) using FTIR.
3.2. CTC capture and detection
Fig. 3A shows the XRF spectrum from magnetically captured
HeLa cells (1105 cells/mL PBS) after exposure to X-rays
for 10 min at 30 kV and 15 mA, where the peaks of bismuth
L-subshell (red) from bismuth nanoparticles can be detected at
10.86 and 13.02 keV against background (black) with a SNR of 5
and 2.5 respectively. The targeting specificity of FA conjugated50nm














Fig. 2. Characterization of nanoparticles. TEM images of bismuth nanoparticles (A) an
PBS (inset shows bismuth nanoparticles in PBS) (C); FTIR spectrum of bismuth nanopananoparticles is confirmed by measuring XRF intensity of bismuth
for HeLa cells and MG-63 cells. Both cell lines, after incubating
with FA conjugated nanoparticles and unmodified nanoparticles,
are washed five times in PBS followed by 10 min X-ray exposure
at 30 kV and 15 mA. Fig. 3B shows XRF counts for the bismuth
peak at 10.86 keV. HeLa cells combined with FA conjugated
bismuth nanoparticles have the strongest XRF peak while HeLa
cells with unmodified bismuth nanoparticles give off signal close
to background (PBS control). This confirms that FA conjugated
bismuth nanoparticles can combine with FRs on surface of HeLa
cells through strong covalent bonds while unmodified nanopar-
ticles are easily removed after PBS wash. To justify whether FA
conjugated bismuth nanoparticles can combine with other cells,
MG-63 cells are taken as a second control because of their low
level of FR expression compared to HeLa cells. Results show that
XRF counts from MG-63 cells, with FA conjugated nanoparticles,
are at similar level as the background obtained from PBS solution.
This confirms that FA conjugated nanoparticles only combine
with cancer cells that over-express FRs.
The sensitivity of detection is obtained by measuring XRF
signals for serially diluted CTC samples (varied from 102, 103, 104,
105 CTCs/mL) in PBS. The measured XRF signals at 10.86 keV are
plotted as a function of the number of CTCs per mL of PBS. Fig. 3C
reveals that the detection sensitivity is 100 CTCs/mL PBS for
40 min X-ray irradiation at 30 kV and 15 mA. The sensitivity can
be further improved by increasing the exposure time. Fig. 3D
shows the net XRF spectra (background removed) collected
from HeLa cells (1102 cells/mL PBS) combined with FA con-
jugated nanoparticles for 20, 40, 100 and 200 min, respectively.100nm













d iron oxide nanoparticles (B); DLS measurements of iron oxide nanoparticles in
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1 HeLa + FA-Bi
2 HeLa + Bi
3 MG-63 + FA-Bi
4 MG-63 + Bi
5 PBS control (background)
*




























* 1 Blood spiked with HeLa + FA-Bi
2 Blood spiked with MG-63 + FA-
Bi
3 Blood control (background)
Fig. 3. CTC capture and detection. XRF spectrum obtained at 30 kV and 15 mA after 10 min exposure of magnetically captured HeLa cells with folic acid conjugated iron
oxide nanoparticles and bismuth nanoparticles (A); Bismuth XRF peak intensity at 10.86 keV of unmodified bismuth nanoparticles (Bi) and folic acid modified bismuth
nanoparticles (FA-Bi) combined with HeLa cells and MG-63 cells (B), * denotes po0.05 when compared with PBS control; XRF counts for bismuth peak at 10.86 keV as a
function of the number of CTCs in 1 mL PBS (C); Net XRF spectrum for HeLa cells conjugated with folic acid modified bismuth nanoparticles collected at 20, 40, 100 and
200 min using 30 kV and 15 mA (D); XRF counts at 10.86 keV for whole blood, blood spiked with 104 MG-63 cells/mL, and 104 HeLa cells/mL, where both types of cell
contain folic acid conjugated bismuth nanoparticles and iron oxide nanoparticles.* denotes po0.05 when compared with blood control (E).
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detection time (Fig. 3D inset).The sensitivity can also be enhanced if
incoming X-rays can be precisely focused onto the captured CTCs
and outgoing X-rays can be oriented with the detector.
The feasibility of the proposed method for clinical applications
has been tested using human blood spiked with CTCs. Results
show that the XRF counts at 10.86 keV for diluted blood sample is
150 (background), while the corresponding values for blood
samples spiked with MG-63 cells and HeLa cells are 180 and
550, respectively (Fig. 3E). Although, the blood samples were
spiked with high concentration of CTCs (104 cells/mL), the results
clearly indicate the promising capabilities of the method in
selectively detecting CTCs with high levels of FR expressions in
whole blood.
3.3. CTC killing through radiation induced DNA damage
Nanoparticles of high atomic number elements can enhance
radiation-induced damage when specifically attached on tumor
cells. Specifically targeted gold nanoparticles can achieve a
nucleus dose enhancement factor of up to 79 and localize ionizing
energy at tumor cells, causing irreversible DNA damages that can
eventually lead to cell death (Hainfeld et al., 2004; Ngwa et al.,
2012; Rahman et al., 2009). Comet assay is often used to quantify
DNA damage by providing complementary damage information
provided by viability assays (MTT) (Karlsson, 2010; Qiao et al.,
2012). The combined effect of bismuth nanoparticles and X-rays
on DNA damage is studied using comet assay on magnetically
captured, and X-ray irradiated HeLa cells. Since the total photo-
electron cross-section of iron for 40 kVp X-rays is 4 times lower
than that of bismuth, the effect of iron oxide nanoparticles on
X-ray induced DNA damage can be ignored. Fig. 4A shows an
optical image of comets from X-ray irradiated (60 min at 40 kVand 100 mA) HeLa cells that have been incubated with a mixture
of functionalized iron oxide nanoparticles and bismuth nanopar-
ticles at 100 mg/mL for 24 h. The presence of long tails means
significant DNA damage. Three sets of control samples are also
tested. In the first set, HeLa cells without nanoparticles are
exposed to X-rays followed by electrophoresis at the same
condition. Tails are observed in the resulting comets (not shown)
after doing the comet assay. For the second control, HeLa cells are
used that contain a mixture of functionalized nanoparticles but
are not exposed to X-rays. Fig. 4B shows the absence of DNA tails
from such cells after electrophoresis, suggesting that DNA damage
is primarily due to X-rays and not the nanoparticles. Third set of
control samples contain untreated HeLa cells without any nano-
particles or X-ray exposure. DNA damage in each sample is
quantified by determining the percentage of DNA in tail
(damaged) and those in entire comet (total), where the amount
of DNA is derived as summation of pixel intensities in the tail or
the entire comet. Fig. 4C compares the level of DNA damages,
where the percentages of DNA in tails are 82.1% with X-rays and
nanoparticles, 63.9% with X-rays alone, 16.9% with nanoparticles
alone, and 10.1% with untreated control. In most cases, the X-ray
induced DNA damages are irrecoverable, eventually leading to
cell death as confirmed by other viability assays. For each set of
HeLa cells mentioned above, MTT assay is carried out after
incubation for 6 h following X-ray irradiation. This is done in
order to confirm cell death induced by DNA damage. Fig. 4D
shows the results of MTT tests where more than 80% of HeLa cells,
which combined with FA conjugated nanoparticles, are killed
when exposed to X-rays for 60 min at 40 kV and 100 mA; how-
ever, only 60% HeLa cells are killed when no nanoparticles is used,
suggesting the dose enhancement is provided by the X-ray
absorbing nanoparticles. As for HeLa cells treated with functio-
nalized bismuth nanoparticles but not exposed to X-rays, less
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Fig. 4. CTC killing through X-ray induced DNA damage. Optical micrograph of comets from X-ray irradiated HeLa cells containing folic acid conjugated iron oxide
nanoparticles and bismuth nanoparticles using 40 kV and 100 mA X-rays for 60 min (A); Optical micrograph of comets from HeLa cells with folic acid conjugated iron oxide
nanoparticles and bismuth nanoparticles without X-ray exposure (B); Mean percentage of DNA in the tail of comets under different conditions (C), * denotes po0.05 when
compared with untreated control (HeLa cells); Results of MTT assay performed on HeLa cells under different conditions (D). * denotes po0.05 when compared with
untreated control (HeLa cells).
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in the untreated control. The MTT results are consistent with
those from comet assay, indicating that X-rays can effectively kill
captured CTCs, which can be enhanced in presence of bismuth
nanoparticles.
Our results clearly indicate the potential use of XRF from
targeted nanoparticles for highly selective detection and on-
demand killing of CTCs in humans. However, several issues need
to be considered before the method can be put to clinical use.
Inherent toxicities and aggregation of both iron oxide nanoparti-
cles and bismuth nanoparticles under in vivo conditions are
needed to be reduced with appropriate surface coatings. For
example, FA conjugated iron oxide nanoparticles that are mod-
ified with dextran and poly (ethylene glycol) (PEG), have shown
enhanced stability and biocompatibility (Sonvico et al., 2005).
Issues such as the circulation time of these nanoparticles and
their excretion from the body should be studied using particles
with different size and surface properties. Future studies will
focus on the effectiveness of the proposed method under in vivo
conditions using mice experiments.4. Conclusion
An integrated approach that combines in vitro collection,
detection and killing of CTCs using bismuth nanoparticles, iron
oxide nanoparticles and X-ray radiation have been demonstrated.
The method uses FA modified nanoparticles for selectively target-
ing CTCs with high levels of FR expression and offers detection
capabilities as low as 100 cells/mL in a buffer solution. The
detection limit can be further improved by increasing the collec-
tion time or by using X-ray focusing optics and appropriate filters
to reduce background noise and increase SNR. Results also show
the potential use of the technique for detecting CTCs in whole
blood, indicating future clinical applications. Use of X-rays allowssimultaneous detection and eradication of CTCs, thus, providing a
novel strategy for management of cancer metastasis.Acknowledgments
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